Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for Simultaneous Treatment of Upper Facial Lines (ULTRA II)
NCT04622254Phase 3Completed
- Sponsor
- Merz
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of incobotulinumtoxinA in upper facial lines (3 arms), sponsored by Merz. Primary endpoints: Percentage of Glabellar Frown Line Responders at Day 30, Percentage of Horizontal Forehead Lines Responders at Day 30 and 1 more. Started Nov 2020; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
upper facial lines
Beyond the preview
Go deeper on NCT04622254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622254.